DAIICHI SANKYO COMPANY, LIMITED
4568・Prime Market・Pharmaceuticals
Governance
Of the 10 directors, 5 are outside directors (outside director ratio of 50%), and since June 2020 an outside director has served as chairman of the Board of Directors. The company has established a voluntary Nomination Committee and Compensation Committee (each composed of 5 outside directors), and as a company with a Board of Corporate Auditors, has put in place an oversight structure consisting of 5 corporate auditors (3 of whom are outside auditors).
Risk Management
A Risk Management Committee has been established based on the "Daiichi Sankyo Group Global Risk Management Policy" to identify and evaluate material risks and manage the progress of countermeasures. Sustainability-related risks such as climate change, human rights, and the supply chain are also integrated into company-wide risk management, with a structure in place to report to the Management Committee and the Board of Directors.
Shareholder Returns
From the 6th mid-term management plan (FY2026-2030), the company has introduced progressive dividends and set an adjusted DOE of 10.0% or higher as the benchmark for dividend levels. Annual dividend for FY2026 (ending March 2026) is ¥78 (up ¥18 year on year), and the forecast for FY2027 (ending March 2027) is ¥100 (up ¥22 year on year). Share buybacks are also implemented flexibly.
Dividend Policy
The basic policy is to determine profit distribution by comprehensively weighing growth investment and shareholder returns, and progressive dividends have been introduced from the 6th mid-term management plan period (FY2026-2030). Under the progressive dividend policy, under which dividends are in principle maintained or increased continuously, the company sets an adjusted DOE (DOE calculated based on adjusted shareholders' equity, which excludes "other components of equity" from shareholders' equity) of 10.0% or higher as the benchmark for dividend levels each fiscal year. The annual dividend for FY2026 (ending March 2026) is ¥78 per share (interim ¥39 + year-end ¥39), and the forecast for FY2027 (ending March 2027) is ¥100 per share annually (interim ¥50 + year-end ¥50). Share buybacks are also positioned as an option for shareholder returns, and while progressive dividends remain the top priority, the company's policy is to implement buybacks flexibly, comprehensively taking into account its financial condition and market environment.
ESG
In addressing climate change, the company has set SBT-certified reduction targets (a 63% reduction in Scope 1 and 2 emissions by FY2030 versus 2015, and net zero by 2050), achieving a 48.6% reduction and a renewable electricity usage rate of 79.9% in FY2025 results. In human capital, the company achieved a female senior executive ratio of 26.9% and an overall engagement survey score of 77 (+2 versus the global benchmark), and has been certified as a Health & Productivity Management Outstanding Organization (White 500) for six consecutive years, demonstrating systematic ESG management across the environmental, social, and human capital domains.
Last updated: July 3, 2026